BioSpace News Archive

Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.

- U.S. Food and Drug Administration (FDA) has authorized the investigational new drug (IND) application - Acute liver and kidney injury are risk factors for poor outcomes in COVID-19 patients - The risk of death from multi-organ failure is present in both patients with severe COVID-19 and those with severe Alcoholic Hepatitis (AH) - Promising Phase 2a clinical results in patients with AH and pre-clinical evidence in multi-organ injury models suggest DUR-928 may be b

Elucid Bio, maker of the FDA-cleared and CE-marked vascuCAP® software, announced today that its novel artificial intelligence (AI) technology demonstrated an over 70 percent improvement in accuracy of stroke prediction as compared to stenosis-based guidelines over a six-year time period

Celsius Therapeutics, a company focused on bringing precision medicine to patients with autoimmunity, cancer and other complex diseases, today announced the signing of three collaboration agreements with the University of Oxford (Oxford, UK), Cleveland Clinic (Cleveland, U.S.) and the LMU University Hospital Munich (Munich, Germany). In each agreement, Celsius will partner with leading academic scientists to access patie

Three American Cancer Society researchers will receive the Real-World Data Impact Award to advance patient-centric research, the ACS and Flatiron Health announced today.

Nephron Research LLC (“Nephron Research”), an independent research provider with leading products in healthcare, is pleased to announce research coverage of the Life Science Tools & Diagnostics sector including coverage of the National Labs and CROs.

TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has priced its previously announced underwritten offering of common stock, comprised of 37,267,080 shares of common stock at a public offering price of $0.35 per share, resulting in gross proceeds of approximately

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYMJEPI ® (epinephrine) Injection 0.3mg and SYMJEPI ® (epinephrine) Injection 0.15mg products through its field sales force. As contemplated by the previously announced termination agreement between Adamis and Sandoz Inc., and the previously announced exclusive distribution and commercializatio

- Renowned leaders in biotechnology, pharmaceuticals, oncology, operations and finance to provide guidance to management team - NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases - NGIO is now a stand-alone public company with plans to list shares on Nasdaq MIRAMAR, Fla., July 01, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology is pleased to announce the Board o

Within a week, NextKidney and its Neokidney portable home hemodialysis system received the PERL Award as well as the Venture Award.